OBJECTIVE: Mild hypothermia has a protective effect on ischemic stroke, but the mechanisms remain elusive. Here, we investigated microRNA (miRNA) profiles and the specific role of miRNAs in ischemic stroke treated with mild hypothermia.
Introduction
I schemic stroke is a leading cause of disability and death worldwide. [1] Although numerous studies have been conducted on the underlying mechanisms of ischemic stroke, [2] [3] [4] [5] [6] they remain to be elucidated. Moreover, tissue plasminogen activator is still the only effective treatment. [1, 7] Hypothermia is known as an effective neuroprotectant, [8] [9] [10] [11] and can be categorized into deep hypothermia (<25°C), moderate hypothermia (30°C-32°C), and mild hypothermia (32°C-35°C). [8] [9] [10] [11] Mild therapeutic hypothermia was shown to be neuroprotective while avoiding serious adverse effects of deep hypothermia, such as shivering and cardiac arrhythmia. [8] Neuroprotective mechanisms of hypothermia may include the reduction of energy failure, decrease of cell death, and promotion of neurogenesis. [8] microRNAs (miRNAs) are single-stranded, noncoding endogenous RNAs with a length of 19-22 nucleotides, which negatively regulate target mRNA expression by either degradation or translational repression. [12] [13] [14] miRNAs regulate essential processes during development and adulthood [15, 16] and are highly conserved in both plants and animals. [15, 16] One miRNA can potentially regulate hundreds of mRNA targets and therefore may be able to affect numerous pathways or cellular processes that involve multiple target genes. [17] miRNAs play important roles as critical regulators of brain development, homoeostasis, and pathological processes. [12] [13] [14] The previous study reported that cerebral ischemia-induced changes of miRNAs involved in angiogenesis, apoptosis, and neurogenesis. [18] These studies also supported the promising potential for miRNAs as novel biomarkers and new targets for stroke. [12] Although miRNAs control a number of conditions and diseases, miRNA profiles after stroke treatment with mild hypothermia still lack proper investigation.
In this study, miRNA profiles were analyzed in rats with cerebral ischemia treated with mild therapeutic hypothermia. Mild therapeutic hypothermia may protect against cerebral ischemia/reperfusion by inhibiting miR-15b expression in rats, making miR-15b a potential target for the future stroke therapies.
Materials and Methods

Animal model
All animal experiments were approved by the Institutional Animal Care and Use Committee of Capital Medical University and conducted in accordance with the principles outlined in the National Institutes of Health (US) Guide for the Care and Use of Laboratory Animals. Male Sprague Dawley rats weighing 280-310 g suffered from transient ischemia for 2 h. The trachea was intubated after rapid inhalation induction of anesthesia with 5% isoflurane in oxygen, and the lungs were mechanically ventilated with 2% isoflurane in 30% O 2 /70% N 2 . Focal ischemia was induced using the intraluminal vascular occlusion method as previously described. [19] Right middle cerebral artery occlusion (MCAO) was performed by inserting 3-0 monofilament nylon suture into the internal carotid artery. For miRNA microarray analysis, sham-operated and MCAO groups were treated with mild hypothermia or normothermia. To ensure the occurrence of ischemia, regional cerebral blood flow was monitored using laser Doppler flowmetry (PeriFlux System 5000, Perimed, Stockholm, Sweden). Blood pressure was monitored through a data acquisition system (MP100A-CE, BIOPAC Systems, Inc., Santa Barbara, CA, USA). All animals were housed in an air-conditioned room at 25°C ± 1°C after recovering from anesthesia. Rectal temperature was measured by a thermocouple probe placed in the rectum and controlled at 37.0°C ± 0.5°C throughout the experiment with a heating lamp and a temperature-regulated heating pad. Brain temperature was measured by means of a thermocouple probe placed close to the skull under the right temporalis. Mild therapeutic hypothermia (33°C ± 0.5°C) was applied by means of ice packs placed around the head/neck and were replaced every hour. Mild therapeutic hypothermia was applied from the time of induction of ischemia for the duration of 3 h.
miRNA microarray
mRNA was isolated from the right cortex using TRIzol (Life Technologies, Carlsbad, CA, USA) and the mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA). The absorbance of all samples was measured at 260 nm and 280 nm. miRNA expression profiling was determined using an Affymetrix Rat miRNA Microarray according to the manufacturer's protocol (Affymetrix, Santa Clara, CA, USA). Briefly, 1 μg total RNA was added to the Poly (A)-tailing. FlashTag Biotin Labeling Kits (Genisphere, Hatfield, PA, USA) were used to label miRNA. Labeled RNAs were hybridized with Eukaryotic Hybridization Control Kit (Affymetrix) and Hybridization, Wash and Stain Kit (Affymetrix) according to the manufacturer's protocol. Microarray was scanned using an Affymetrix GeneChip Scanner (Affymetrix).
miRNA microarray data analysis
The miRNA microarray data were analyzed using a miRNA microarray analysis program obtained from Affymetrix GeneChip Command Console (Affymetrix).
Quantitative reverse transcription-polymerase chain reaction validation of miRNA expression
Total RNA was extracted from brain tissues using TRIzol (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Then, 1.5% formaldehyde denaturing agarose gel electrophoresis was used to detect the quantity of total RNA. RNA was reverse-transcribed to cDNA with the stem-loop RT primer using the M-MLV reverse transcriptase (Promega, Madison, WI, USA). Quantitative polymerase chain reaction (PCR) was carried out using AmpliTaq Gold Enzyme (Applied Biosystems, Austin, TX, USA). The miRNA universal sense primer was 5ʹ-GTGCAGGGTCCGAGGT-3ʹ. The RT primer of rno-miR-15b was 5ʹ-GTCGTATCC AGTGCAGGGTCCGAGGTATTCGCACTGGATAC GACTGTAAA-3ʹ; antisense primer of rno-miR-15b was 5ʹ-ACGTAGCAGCACATCATGGTTT-3ʹ; RT primer of rno-miR-598-3p was 5ʹ-GTCGTATCCAG TGCAGGGTCCGAGGTATTCGCACTGGATACGA CTAACGA-3ʹ; antisense primer of rno-miR-598-3p was 5ʹ-TCTACGTCATCGTCGTCATCG-3ʹ. U6 was amplified as the internal control by forward primer 5ʹ-CTCGCTTCGGCAGCACA-3ʹ, and reverse primer 5ʹ-AACGCTTCACGAATTTGCGT-3ʹ. Reverse transcription (RT) reactions were incubated for 10 min at 16°C, 30 min at 37°C, and 5 min at 65°C. The real-time PCR protocol was used as follows: 95°C for 10 min, followed by 40 cycles at 95°C for 15 s, 60°C for 30 s, and 70°C for 30 s.
Cells culture and oligonucleotide transfection
PC12 cells were incubated in RPMI 1640 (Gibco, Life Technologies, Gaithersburg, MD, USA) with 10% horse serum (Gibco), 5% fetal bovine serum (Gibco), and 100 U/ml penicillin/streptomycin (Life Technologies). Cells were maintained at 37°C and 5% CO 2 . miR-15b mimic and control were purchased from Life Technologies. PC12 cells were inoculated at a density of 3.5 × 10 5 per well in six-well plates and were transfected using Lipofectamine RNAiMAX (Life Technologies) when they reached 60% confluence. Cells were collected at 24, 48, and 72 h after miRNA transfection. Three independent replications were performed for all experiments.
Western blot analysis
Cells were collected at 0, 24, 48, and 72 h after miRNA transfection, and tissues were collected 24 h after ischemia. Cells and tissues were lysed in lysis buffer (10 mM Tris-HCl, 150 mM NaCl, 600 mM NP-40, 5 mM EDTA, and 2% TritonX100). The lysates were cleared by centrifugation and boiled with sodium dodecyl sulfate (SDS)-sample buffer. Protein concentration was determined using a bicinchoninic acid assay protein assay kit (Pierce, Rockford, IL, USA). Samples were separated on SDS-polyacrylamide gels and transferred to nitrocellulose membranes using semi-dry blotting. Protein samples (100 μg per lane) were separated on a 12% SDS-polyacrylamide gel. Rabbit anti-ADP ribosylation factor-like 2 (Arl2) polyclonal antibody was used (1:200 dilution, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). The blots were visualized by chemiluminescence (Millipore, Billerica, MA, USA). Antiactin antibody was used as an internal loading control. The relative optical density of protein bands was measured using Image-Pro Plus Analysis Software (Media Cybernetics, Inc., Rockville, MD, USA).
Infarct volume analysis
Infarct volume was determined by 2,3,5-triphenyltetrazolium chloride (TTC) as previously described. [20] Six coronal brain sections (2-mm thick) were sliced using a brain matrix. Coronal sections were incubated in a 2% TTC-saline solution for 30 min at 37°C, and then, fixed in 4% paraformaldehyde/phosphate-buffered saline. TTC staining patterns were photographed at 24 h after fixation and were then analyzed using Image-Pro Plus Analysis Software.
Neurological function assessment
Neurological functional deficits were assessed at 24 h after reperfusion in a blind fashion as previously described. [21, 22] Neurological functions were graded on a scale from 0 to 12 (normal score, 0; maximal score, 12).
Measurement of cellular and tissular adenosine triphosphate
The amount of adenosine triphosphate (ATP) in the cell lysates was measured using an ATP assay kit (Beyotime Biotechnology, China) in accordance with the manufacturer's instructions.
Intracerebroventricular injection
miRNA mimics were purchased from Life Technologies. Seventy adult male Sprague Dawley rats were randomly assigned into four groups: 37°C + control mimic group (n = 17), 37°C + miR-15b mimic group (n = 17), 33°C + control mimic group (n = 18), and 33°C + miR-15b mimic group (n = 18). Intracerebroventricular injection was performed 60 min before cerebral ischemia as previously described. [23] The coordinates from bregma and pial surface from the tip of the injection needle were anteroposterior = −0.8 mm; mediolateral = +1.5 mm; dorsoventral = −3.2 mm. A volume of 10 μM miRNA in a total volume of 10 μl including 2 μl Lipofectamine 2000 was injected 30 min before MCAO surgery.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 7 software (GraphPad Software Inc., La Jolla, CA, USA). All data are reported as mean ± standard error of mean. The significance of difference was assessed by one-way analysis of variance and Tukey's multiple comparisons test. Statistical significance was set at a value of P < 0.05.
Results
Total RNA quality
Total RNA was extracted from the ipsilateral cortex of MCAO rats treated with normothermia and mild hypothermia. The quality of total RNA was evaluated by the A260/A280 ratio, which was in the range of 1.8-2.0 (data not shown). To detect the RNA integrity, formaldehyde denaturing gel electrophoresis was performed. The results showed that the 28S and 18S bands were bright and that 28S: 18S RNA bands were greater than or close to 1:1 [ Figure 1a ]. These data confirmed that the quality of RNA reached the requirements of miRNA array analysis.
Microarray analysis
The hierarchical clustering was shown as Figure 1b . Selective upregulation (>1.5-fold) or downregulation (<0.7-fold) were determined by comparisons with the control and hypothermia group. In our screen of the miRNA transcriptome, we found that two miRNAs, rno-miR-15b (fold change: 0.6654) and rno-miR-598-3p (fold change: 0.5693) were significantly decreased at 24 h after cerebral ischemia.
Quantitative polymerase chain reaction validation
To validate the expression of miRNAs in stroke treated with mild hypothermia, we detected the expression of rno-miR-15b and rno-miR-598-3p by RT-PCR. As shown in Figure 2a and b, rno-miR-15b and rno-miR-598-3p were downregulated at 24 h after cerebral ischemia treatment with mild hypothermia.
miR-15b overexpression inhibited the expression of its target ADP-ribosylation factor-like 2 and adenosine triphosphate levels in PC12 cells
To investigate the effect of miR-15b on its target Arl2 and ATP levels, [24] miR-15b mimic and control were transfected to PC12 cells. As shown in Figure 3a and b, miR-15b mimic decreased the expression of Arl2 at 24 h and 48 h after transfection (P < 0.01 and P < 0.01, respectively). Moreover, miR-15b mimic attenuated ATP levels in PC12 cells at 24 h and 48 h after transfection (P < 0.01 and P < 0.05, respectively).
miR-15b overexpression increased infarct volume and aggravated functional outcomes in cerebral ischemia of rats treated with or without mild therapeutic hypothermia
To assess the effect of miR-15b on cerebral ischemia and mild hypothermia-mediated neuroprotection, miR-15b mimic or control miRNA was injected into the ipsilateral ventricle of MCAO rats treated with normothermia and mild hypothermia 60 min before the beginning of ischemia. TTC staining and neurological severity assessment were performed at 24 h after reperfusion. As shown in Figure 4a and b, infarct volume in the miR-15b mimic plus normothermia group was increased significantly compared to the control mimic + normothermia group (P < 0.05). miR-15b mimic aggravated the neurological function compared to control mimic at normothermia [ Figure 4c ]. The 33°C + miR-15b mimic group had increased infarct volume (P < 0.01) [ Figure 4a and b] and aggravated neurological function (P < 0.05) [ Figure 4c ] compared with the 33°C + control mimic group.
miR-15b overexpression inhibited the expression of its target ADP ribosylation factor-like 2 and ATP levels in middle cerebral artery occlusion rats under normothermia or hypothermia
To further explore the role of miR-15b on stroke treated with mild hypothermia in vivo, Western blot was performed to evaluate the protein level of its target Arl2 and tissular ATP levels using an ATP assay kit. As shown in Figure 5a and b, the expression level of Arl2 was decreased significantly in the 37°C + miR-15b mimic group compared with the 37°C + control mimic group (P < 0.05). Tissular ATP levels had a decreased trend in the 37°C + miR-15b mimic group, but did not reach statistical significance (P = 0.086) [ Figure 5c ]. The Arl2 and ATP expression levels in the 33°C + miR-15b mimic group were lower than in the 33°C + control mimic group (both P < 0.001) [ Figure 5 ].
Discussion
In this study, we investigated the miRNA profile following cerebral ischemia treated with mild therapeutic hypothermia and identified specific miRNA changes at 24 h after ischemia. Our results demonstrate that mild therapeutic hypothermia protected the brain against miRNAs have been proposed as novel biomarkers and therapeutic targets for stroke. [25] Although we only detected a small amount of differentially expressed miRNAs, we verified the expression of two miRNAs, rno-miR-598 and rno-miR-15b. A recent study reported that miR-598 inhibited Notch2 expression [26] while Notch2 may regulate ischemia/reperfusion-associated production of injurious reactive oxygen species, cell death, and inflammation. [27, 28] However, the exact role of miR-598 after stroke is still unknown and needs to be further explored. In a similar study in cardiac myocytes, miR-15b was downregulated and modulated cellular ATP levels through Arl2. [24] miR-15b has many mRNA targets, such as Bcl-2, interleukin-15, and Cyclin D1, which are related to apoptosis, inflammation, and cell growth. [29] [30] [31] Thus, the destructive role of miR-15b after stroke may depend on several mRNA targets and may not be confined to Arl2.
As a member of the ARF family and RAS superfamily of regulatory GTPases, [32] Arl2 is highly conserved in eukaryotes and highly expressed in the brain. [33] Arl2 is associated with mitochondrial functions such as mitochondrial morphology, motility, and maintenance of ATP levels. [32] In addition, Arl2 plays a vital role in microtubule dynamics, [34] apoptosis, [35] cell cycle progression, [36] asymmetric division of neural stem cells, [37] and survival of neural progenitor cells. [35] Brain tissues demand high energy to sustain homeostasis. [38] Cerebral ischemia leads to mitochondrial dysfunction, ATP depletion, cytoskeletal disruption, and ultimately necrosis or apoptosis. [39, 40] ATP depletion occurs within a very short period in cerebral ischemia and triggers plasma membrane depolarization. [38, 39] Mild therapeutic hypothermia has a neuroprotective effect on stroke by lowering the metabolic rate and energy consumption, such as prevention of ATP depletion. [41] Our results showed that mild hypothermia may maintain relatively high levels of ATP and that miR-15b transfection decreased ATP levels after stroke treatment with mild hypothermia. A previous study showed that ATP treatment has a striking detrimental impact on cerebral ischemia by inducing mild hypothermia, [42] which contradicts our results. In fact, mild hypothermia facilitated ATP recovery following cerebral ischemia in gerbils. [43] The previous studies reported that cerebral ischemia led to a decrease in intracellular ATP levels, but an increase in extracellular levels. [44] [45] [46] In the present study, we only detected cellular ATP levels and did not distinguish between extra-and intracellular ATP locations. Thus, the relationship between mild hypothermia and intracellular and extracellular ATP levels should be investigated in more detail.
Several limitations of our study deserve mentioning. First, miR-15b inhibitor was not applied to detect the role of miR-15b, which may provide neuroprotection after stroke. Second, because sham-operated groups treated with normothermia or hypothermia do not differ in apoptosis and the expression level of many proteins related to energetic metabolism, [47] [48] [49] sham-operated groups treated with hypothermia were not included as a control group. Third, our study did not provide a direct causal relationship between the observed changes in miRNA expression and ATP levels. It is well known that mild hypothermia therapy can reduce the volume of cerebral infarction and improve the neurological function after stroke, but the effect size of the differentially expressed miRNAs is too small. Thus, further studies are needed to clarify the reason for the small number of differentially expressed miRNAs in cerebral ischemia treated with mild therapeutic hypothermia.
Conclusions
In summary, we provide a dataset of miRNA expression after stroke treatment with mild hypothermia and normothermia. Mild therapeutic hypothermia protects against cerebral ischemia/reperfusion by inhibiting miR-15b expression, which may serve as a novel target for stroke therapy.
